Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (160)
  2. Journal Article (105)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Department of Medicine (285)
  2. Solid Tumor Oncology Division (285)
  3. Thoracic Oncology (285)
  4. GSK Faculty (119)
  5. Department of Pathology and Laboratory Medicine (102)
  6. Human Oncology and Pathogenesis Program (100)

More Groups

People
  1. Gregory Riely (107)
  2. Mark Kris (94)
  3. Marc Ladanyi (71)
  4. Charles Rudin (57)
  5. Maria Arcila (55)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (14)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Journal of Thoracic Oncology (62)
  3. Annals of Oncology (26)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (84)
  2. American Society of Clinical Oncology (82)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (30)
  5. Nature Publishing Group (11)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (285)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC
    Meeting Abstract

    Planchard, D.; Yu, H. A.; Yang, J. C. H.; Lee, K. H.; Lopez, P. G.; Park, K.; Kim, J. H.; Lee, D. H.; He, S.; Chao, B. H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers
    Meeting Abstract

    Offin, M. D.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez Vega, F.; Kris, M. G.; Rudin, C. M.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC)
    Meeting Abstract

    Marcoux, N.; Gettinger, S. N.; O'Kane, G. M.; Arbour, K. C.; Neal, J. W.; Husain, H.; Evans, T. L.; Brahmer, J. R.; Muzikansky, A.; Bonomi, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Offin, M. D.; Feldman, D. L.; Ni, A.; Lai, W. C. V.; Arbour, K. C.; Daras, M.; Pentsova, E.; DeAngelis, L. M.; Beal, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Janne, P. A.; Yu, H. A.; Johnson, M. L.; Vigliotti, M.; Shipitofsky, N.; Guevara, F. M.; Chen, S.; Yu, C.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Somwar, R.; Rekhtman, N.; Benayed, R.; Chang, J. C.; Plodkowski, A.; Lui, A. J. W.; Eng, J.; Rosenblum, M.; Li, B. T.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Planchard, D.; Janne, P. A.; Yu, H. A.; Moro-Sibilot, D.; Goldberg, T.; Gu, X.; Li, J.; McGill, J.; Yu, C.; Slosberg, E.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Jänne, P.; Yu, H.; Shipitofsky, N.; Vigliotti, M.; Goldberg, T.; Li, J.; Mcgill, J.; Zhang, H.; Yu, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Meeting Abstract

    Jänne, P.; Yu, H.; Johnson, M.; Steuer, C.; Vigliotti, M.; Shipitofsky, N.; Guevara, F. M.; Chen, S.; Yu, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save